Saskatoon, Saskatchewan--(ACN Newswire via SeaPRwire.com - April 27, 2026) - Buffalo Potash Corporation (TSXV: BUFF) (OTCQB: BLPTF) (the "Company" or "Buffalo") is pleased to announce the completion of a Preliminary Economic Assessment ("PEA") and concurrent release of its maiden 43-101 Mineral Resource Estimate for its 100%-owned Disley Potash Project (the "Disley Project"), located in Saskatchewan, Canada.The PEA has been filed and can be found under the Company's profile on SEDAR+ (www.sedarplus.ca) and on the Company's website (www.buffalopotash.ca).PEA & Mineral Resource Estimate Highlights Total production of 1,000,000 tonnes per annum (TPA) of K62 granular-grade Muriate of Potash (MOP) and 125,000 TPA of K62 soluble grade MOPAfter-tax NPV(1)(8) of US$1.1B and IRR(1) of 30%US$639M initial CAPEX estimate, including US$128M in contingencyEstimated US$55/t MOP OPEX (Table 4)Measured and indicated tonnage of 1,671.5 million metric tonnes at an average grade of 34.8% KCl, yielding 582 million tonnes of KClOver 50 years of mine life at 1,125,000 TPA based on current resource estimate (Table 2)(2)The advancement of a Feasibility Study ("FS") for Disley East and Disley West (the "HLD Mines") will run concurrent with Initial Production Module ("IPM") construction, with FS completion representing the key decision gate for proceeding to construction of Disley East and Disley West(3)(2) Based on Measured and Indicated resource estimate of 582Mt at 34.8% KCl.(3) The PEA does not constitute a feasibility study and does not demonstrate economic viabilityMr. Steve Halabura P.Geo., Buffalo Chief Executive Officer, commented: "Since founding Buffalo Potash in 2018, the team and I have invested years of disciplined work — geological, technical, and strategic — to systematically unlock the potential of modular selective solution potash mining in Saskatchewan, the key being Buffalo's Disley Project. Having spent my career working in Saskatchewan potash, I had a strong conviction from the beginning that Disley had a substantial resource endowment, and this Mineral Resource Estimate confirms exactly that. The PEA illustrates both low capex per tonne and operating cost per tonne, as well as setting a new environmental standard for how potash production should look in the 21st century — no tailings stored on surface and minimal freshwater usage." Mr. Halabura continued: "The team and I believe the Disley Project represents the next generation of Saskatchewan potash solution mining and are excited to begin development of the Initial Production Module, which will be the first leg of this buildout and is expected to bring soluble-grade potash production online within the next 12 months. During the development of the Initial Production Module, we will also test our patent-pending Vortex Crystallizer, alongside an industry standard crystallizer, which has the potential to significantly reduce the capex of the Initial Production Module and further potential build-outs. With global attention turning to the security of critical supply chains, the urgency to bring reliable, jurisdiction-stable potash production online has never been greater. This is a proud moment for our team, our shareholders, and the stakeholders that have supported us along the way — and we are just getting started."Table 1: PEA SummaryLine ItemUnitsTotal Project Production Rate MOPTPA1,000,000Production Rate Soluble GradeTPA125,000Total Initial CAPEXUS$ million639CAPEX per Tonne CapacityUS$/tonne568Average Unit OPEXUS$/tonne55MOP Price (25-year avg.)US$/tonne393.6(4)Soluble Grade Price (25-year avg.)US$/tonne373.6(5)Pre-Tax NPV(1) (8%)US$ million1,534.67Pre-Tax IRR(1)%35Post-Tax NPV(1) (8%)US$ million1,085.47Post-Tax IRR(1)%30Steady-State Annual RevenueUS$ million442.5Steady-State Annual EBITDAUS$ million251.0 (4) LoM average price of Granular MOP, produced by Disley East and Disley West(5) LoM average price of Soluble Grade MOP, produced by IPMThe PEA is preliminary in nature and includes inferred mineral resources, which are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. There is no certainty that the PEA will be realized.PEA & Mineral Resource Estimate OverviewThe PEA was prepared by Micon International Co Limited ("Micon") in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects and evaluates the development of the Disley Project as a phased potash solution mining operation. The PEA has an effective date of April 15, 2026 and is based on a Mineral Resource Estimate ("MRE") developed concurrently by Micon with an effective date of April 15, 2026, incorporating historical assay data from legacy drilling programs as well as results from Buffalo Potash's 2026 confirmation drill program. The PEA contemplates a phased development approach across three production facilities on the Disley property:The Initial Production Module ("IPM") - is a low-capital entry point designed to bring 125,000 tonnes per year of soluble grade MOP to market;Disley East - a full-scale HLD Mine on the east segment of the Disley Project, with a production capacity of 500,000 tonnes per year of granular MOP; andDisley West - a full-scale HLD Mine on the west segment of the Disley Project, with a production capacity of 500,000 tonnes per year of granular MOP.Successful construction of the IPM is anticipated to provide technical data used in the completion of the concurrent FS and would, subject to the results from the FS and a positive construction decision, be followed by the potential concurrent development of the Disley East and Disley West HLD solution mines. If fully developed, the Disley Project is designed to have the capacity to produce 1,000,000 TPA of granular MOP and 125,000 TPA of soluble grade MOP ("Full Production Capacity").The MRE indicates a resource base that substantially exceeds the project's current design requirements, which, if successfully developed, would position the Disley Project as a long-life asset. This is consistent with the generational mine lifecycles typically associated with Saskatchewan potash operations, though there is no certainty that resources will be converted to reserves or that any particular mine life will be achieved.Table 2: Mineral Resource EstimateCategoryTonnage (Mt) Avg KCl GradeAvg K2O GradeKCl (Mt)K2O (Mt)Measured399.734.82%22.00%139.287.9Indicated1,267.434.84%22.01%441.5278.9Inferred2,663.234.96%22.08%930.9588.1 Table 2 Notes:The effective date of this MRE is April 15, 2026.Dr. Ryan Langdon, Ph.D, CGeol, of Micon is the QP responsible for this MRE.The MRE has been classified in the Measured, Indicated and Inferred categories.An average specific gravity (SG) value of 2.08 g/cm3 was used.Conversion between KCl and K2O was made using the formula KCl = K2O * 1.583The MRE used economic assumptions for HLD mining. A deduction was made to account for the presence of mining anomalies not detected by existing drill holes and seismic lines. The values used are 5% for Measured, 9% for Indicated and 25% for Inferred.The block model supporting the resource is orthogonal and has a block size of 50 m x 50 m x 0.9 m.The mineral resources described above have been prepared in accordance with the current Canadian Institute of Mining, Metallurgy and Petroleum Standards and Practices.Numbers have been rounded to the nearest million tonnes. Differences may occur in totals due to rounding.Mineral Resources are not Mineral Reserves as they do not have demonstrated economic viability. The quantity and grade of reported Inferred Mineral Resources are uncertain in nature and there has been insufficient exploration; however, it is reasonably expected that a significant portion of Inferred Mineral Resources could be upgraded into Indicated Mineral Resources with further exploration.Micon's QP has not identified any legal, political, environmental, or other factors that could materially affect the potential development of the mineral resource estimate.Figure 1: Core Samples from the 7-10 Hole on the Disley ProjectTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/12107/294332_592822e3642ebbb0_001full.jpgMining MethodBuffalo intends to develop the Project using solution mining, a well-established approach that has been successfully deployed across Saskatchewan for more than 50 years. Solution mining is widely recognized as a reliable and efficient technique for extracting potash from laterally continuous deposits, notably used at both neighboring properties of the Disley Project — the K+S Bethune mine and the Mosaic Belle Plaine mine.Building on this proven foundation, Buffalo holds a patent on an enhanced solution mining approach known as Horizontal-Line-Drive Selective Solution Mining ("HLD Mining"), which is the installation of commercially proven oil and gas injection systems within horizontal wells. This method is designed to optimize efficiency, reduce overall capital intensity, and significantly limit freshwater requirements, while remaining grounded in the principles of traditional solution mining.Following underground dissolution, potash-rich brine is recovered to surface and processed through crystallization, drying, and compaction to produce a finished potash product ready for local delivery or export via existing road and rail infrastructure that currently runs adjacent to the Disley Property.Initial Capital Expenditure (CAPEX) The initial capital cost estimate has been prepared in line with the Class 4 definition outlined by AACE International standards, with a contingency of 25% applied to the IPM, Disley East, and Disley West components.Mechanical equipment represents the largest component of initial capital expenditure at approximately 38% of Total Project initial CAPEX. For Disley East and Disley West, the mechanical scope encompasses the full processing train required to produce export-grade granular MOP, including crystallization, debrining and drying, compaction and glazing, soluble product screening, and product storage and loading. For the IPM, the mechanical scope includes a crystallizer, pumps, tanks, pipework, centrifuge, dryer, and baghouse. Total initial capital expenditure across all three facilities is US$639 million, as summarized in the table below.Table 3: Initial CAPEX SummaryDescription IPMDisley EastDisley WestTotal Project(US$ million)(US$ million)(US$ million)(US$ million)Site Works0.711.311.323.3Concrete-5.65.611.2Structural Steel1.29.39.319.9Mechanical15.1113.3113.3241.7Piping0.214.914.930.0Electrical-15.015.029.9Instrumentation0.12.92.95.9Architecture0.019.619.639.2Minor Mechanical4.72.42.49.4General Construction1.413.313.328.0Indirects-36.136.172.3Contingency5.860.960.9127.7Total Capital Expenditure(6)29.2304.7304.7638.6 (6) For modelling purposes, the total capital expenditure estimate for the PEA assumes use of an industry standard crystallizer instead of Buffalo's patent-pending Vortex Crystallizer.Sustaining capital of US$483 million (US$17/t MOP) over the life of mine comprises an annual provision of 2% of original fixed plant and surface infrastructure costs, plus US$10/t MOP for the drilling, completion and tie-in of replacement wells — the dominant component of sustaining capital — based on each set of three wells yielding 500,000 tonnes over an approximate 5-year useful life.Operating Expenses (OPEX)Buffalo Potash's estimated operating cost of US$55/t MOP reflects the structural advantages of operating in Saskatchewan, a mature potash jurisdiction with competitive industrial energy rates, an established skilled workforce, and existing road and rail infrastructure adjacent to the Disley Property enabling low-cost delivery to both domestic and export markets. Buffalo management anticipates these fundamentals position the Disley Project to be among the lowest-cost potash producers upon reaching full production.Table 4: OPEX SummaryItemDescription1,125,000 TPA(US$ million)IPM Contingency$14.49/t applied to IPM production only1.8Wellfield Power500 Hp at $0.063/kWh1.8Processing Power19,356 Hp at $0.063/kWh18.0Drilling$25,000/day; 45 days/yr0.1Pipes, Pumps, ValvesSteaming & general maintenance0.8InstrumentationMonitoring & controls0.4Labour32 staff7.8Natural Gas$386/1000m³ incl. carbon tax19.6Maintenance5% of major equipment capital5.4ReagentsDedust oil & anticake amines2.0Water$2.20/m³; 45 m³/hr1.3General & Admin SupervisionManagement & safety1.9Admin SuppliesOffice & admin supplies0.8Total Annual OPEX61.7OPEX US$/t MOP55 / tonne Economic AssumptionsThe economic analysis evaluates the Disley Project as a phased development consisting of the IPM to establish early cash flow, followed by the full-scale HLD Mine comprising Disley West and Disley East. The IPM was evaluated as a standalone project, with the HLD Mine (Disley East and Disley West) assessed on an incremental basis and in combination with the IPM as an overall project. A Discounted Cash Flow ("DCF") model was constructed with the following assumptions:All costs and revenues are expressed in constant, first quarter 2026 money terms, with no provision for escalation or inflation;Capital and operating cost estimates denominated in Canadian dollars have been converted to US dollars at an exchange rate of CAD 1.38 per USD;A discount rate of 8% has been applied on an all-equity basis;The pre-tax results presented include the Saskatchewan Potash Production Tax (PPT) and royalties but exclude federal and provincial corporate income tax. The after-tax results include corporate income tax (Saskatchewan 12%, Federal 15%);The IPM ramps up over 3 months at 50% of nominal capacity; Disley West and Disley East have a 6-month ramp-up period at 50% of capacity, with the Disley East being deferred by a 3-month offset from the West Section;It is assumed the IPM is scheduled to begin construction July 2026 with commercial operations starting January 2027;It is assumed that a positive construction decision will be reached on Disley West and Disley East. Disley West is scheduled to begin construction July 2027, with operations beginning July 2029. Construction at Disley East is scheduled to be the final facility developed, with construction beginning October 2027 and operations beginning October 2029;Soluble grade MOP produced by the IPM is sold locally, incurring a transport cost of US$10/t compared to US$43/t for export grade granular MOP railed FOB Vancouver; soluble grade MOP is priced at a US$20/t discount to granular, reflecting a life-of-mine average of US$373.6/t versus US$393.6/t FOB Vancouver;In addition to MOP, the IPM will produce 50,000 m³ per year of KCl brine that may be attractive to regional oilfield services customers at an average transport cost of US$10/m³;Payback period is measured from the start of construction to the point at which cumulative cash flow turns positive; andAlthough the project's mine life is anticipated to extend beyond a 25-year time frame, the NPV(1) and IRR(1) calculations reflect a 25-year "LoM" period.The primary input parameters for the DCF model are outlined in the table below.Table 5: Summary of Inputs for Economic AnalysisInput ParametersUnitValueEvaluation Base Date - IPMDate2026-07-01Evaluation Base Date - Disley East & Disley WestDate2027-07-01Sales: HLD Mine MOP Sales (granular)TPA1,000,000Sales: IPM MOP (soluble)TPA125,000Sales: KCl Brinem3/yr50,000Price: Granular MOP (FOB Vancouver) 25-year averageUS$/t394Price: Soluble MOP 25-year averageUS$/t374Price: KCl BrineUS$/m343Transport Costs: Granular MOPUS$/t43Transport Costs: Soluble MOPUS$/t10Transport Costs: KCl BrineUS$/m310Corporate Tax (Sask. + Canada)%27%Contingency for CAPEX%25%Discount Rate%8%NPV calculationYears25 The Disley East and Disley West mines have a start date of construction later than that of the Initial Production Module, and their IRR(1), NPV(1) and Payback periods are all calculated from that later date, while the overall Project results reflect the start date of the IPM. The individual IPM phase has a payback period of 1.1 years, while Disley East and Disley West each respectively have payback periods of 2.9 years. The total Project payback of 4.7 years reflects an earlier calculated start date at the time of first production at the IPM, prior to first production from Disley East and Disley West.Table 6: Summary of OutputsMetricUnitTotal ProjectInitial CAPEXUS$ million639OPEXUS$55 / tonnePre-Tax NPV(1) (8)US$ million1,534Pre-Tax IRR(1)%35%Post-Tax NPV(1) (8)US$ million1,085Post-Tax IRR(1)%30% The Disley ProjectThe Disley Project is located approximately 50km northwest of Regina and covers 10,610 hectares (Crown and Freehold mineral rights). The property is situated immediately adjacent to the east of the K+S Bethune potash solution mine and north of the Mosaic Belle Plaine potash solution mine — both of which are amongst the largest producing potash solution mines in the world. In the opinion of management, the Disley Project is in one of the most favorable areas of Saskatchewan for potash solution mining (see Figure 2) as evidenced by the success of these neighboring projects(6).Figure 2: The Disley Property Situated Amongst Major Potash Solution Mines(7)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/12107/294332_592822e3642ebbb0_002full.jpgAbout Buffalo PotashBuffalo Potash is an emerging Saskatchewan-based potash developer pursuing a modular approach to selective solution mining through its patented Horizontal Line-Drive (HLD) technology. Buffalo is advancing the Disley Project — located next to several of the most prominent currently producing potash solution mines in the world — with the objective of establishing capital-efficient, lower-impact potash production in one of the world's leading potash jurisdictions.Qualified PersonThe scientific and technical information contained in this news release has been reviewed and approved by Douglas F. Hambley, PhD, PE, P.Eng., PG, an independent consultant of the Company and Qualified Person as defined under NI 43-101 Guidelines. Dr. Hambley is a globally recognized expert in potash geology and mine development and has assisted Micon in their preparation of the MRE and PEA.All related and pertinent information has also been reviewed for this news release by Jared Galenzoski, P.Geo, FIMMM as an independent consultant and Qualified Person as defined under NI 43-101. Mr. Galenzoski is also an expert in several potash-related fields and has assisted Micon in their preparation of the MRE and PEA.Technical Report and Qualified PersonsFor more information in respect of the Disley Project, including with respect to key assumptions, parameters, and methods used to estimate the MRE, data validation and QA/QC procedures, and the basis, qualifications and assumptions for the PEA, please refer to the entirety of the Technical Report prepared by Ryan Langdon, PhD, P.Geol.; Jack Nagy, PEng; Christopher Jacobs, CEng., MIMMM; and Richard Thompson, CEng, MiChemE. Each of the aforementioned persons is considered a "Qualified Person" for the purposes of NI 43-101 and has reviewed and approved the scientific and technical disclosure contained in this news release. No limitations were imposed on their verification process. Readers are cautioned to review the entirety of the PEA as it contains additional disclosures material to the matters discussed in this press release.Notes(7) The K+S Bethune potash solution mine and north of the Mosaic Belle Plaine potash solution mine (together, the "Adjacent Properties") may each be considered an "adjacent property" (within the meaning of NI 43-101) to the Company's Disley Project. The Company does not have any interest in either of the Adjacent Properties. The Company believes this context is useful in illustrating the proven endowment of the district, while noting that mineralization on adjacent or nearby properties is not indicative of mineralization on the Company's Disley Project. There is no guarantee that the Disley Project will yield comparable results to any of these mines.ContactSteve Halabura, P.Geo. | Chief Executive Officer & DirectorEmail: steve@buffalopotash.ca | Phone: 1-306-220-7715(1) Non-GAAP Financial MeasuresNet Present Value ("NPV") and internal rate of return ("IRR") are forward-looking financial measures used by management to evaluate the economic potential of the Disley Project, as estimated in the PEA. These measures do not have standardized definitions under IFRS and may not be comparable to similar measures disclosed by other issuers.NPV represents the sum of discounted future after-tax cash flows projected over the 25-year evaluation period at a discount rate of 8%, net of initial and sustaining capital expenditures. The most comparable IFRS measure is net income (loss); however, NPV is a forward-looking measure that reflects projected future cash flows and cannot be directly reconciled to historical net income. IRR represents the discount rate at which NPV equals zero across the project's projected cash flows.These measures should not be construed as alternatives to net income, comprehensive income, or cash flows from operations as determined in accordance with IFRS. Readers are cautioned that these measures reflect PEA-level estimates and are subject to the risks and uncertainties disclosed under "Forward-Looking Information" below.Forward-Looking InformationThis news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward-looking information is generally identifiable by the use of words such as "believes," "may," "plans," "will," "anticipates," "intends," "could," "estimates," "expects," "forecasts," "projects," "targets," "schedules," or similar expressions, and the negative of such expressions.Forward-looking information in this news release includes, but is not limited to, statements regarding: the results, assumptions, and projections contained in or derived from the PEA and Mineral Resource Estimate for the Disley Project, including projected production rates, capital and operating costs, NPV, IRR, payback periods, and mine life; the anticipated timing and phasing of construction and commercial production for the IPM, Disley East, and Disley West; the Company's ability to secure permitting, financing, and all necessary regulatory approvals; the anticipated cost and technical performance of the HLD Mining method; expectations regarding MOP and soluble grade potash pricing, transportation costs, and market access; and the Company's broader development plans and strategy for the Disley Project.Forward-looking information is based on management's reasonable assumptions, estimates, analysis, and opinions made in light of its experience and perception of historical trends, current conditions, and expected future developments, as well as other factors that management believes are relevant and reasonable in the circumstances as of the date such statements are made. Key assumptions underlying the forward-looking information include, but are not limited to: the accuracy of the Mineral Resource Estimate and PEA, including geological, engineering, and cost assumptions; no material adverse changes to commodity prices, exchange rates, or tax and royalty regimes; the availability of financing on acceptable terms; the Company's ability to obtain necessary permits and approvals on anticipated timelines; and the continued availability of equipment, personnel, and infrastructure.Forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied, including: the inherent uncertainty of PEA-level studies and the possibility that actual capital costs, operating costs, and production rates differ materially from estimates; changes in potash or fertilizer market prices; fluctuations in currency exchange rates, particularly the Canadian dollar relative to the US dollar; the risk that permitting, financing, or regulatory approvals are not obtained on anticipated timelines or at all; risks related to the development, commissioning, and operation of novel mining technology; risks inherent to solution mining operations; and general business, economic, competitive, political, and social risks and uncertainties.A PEA is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as Mineral Reserves. There is no certainty that the PEA will be realized. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended. The forward-looking information contained herein is made as of the date of this news release, and the Company disclaims any obligation to update or revise such information except as required by applicable securities laws.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294332 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 27, 2026 - (ACN Newswire via SeaPRwire.com) - Standard Chartered and the Hong Kong Trade Development Council (HKTDC) jointly released the latest Standard Chartered Greater Bay Area Business Confidence Index (GBAI), revealing that business sentiment among companies in the Greater Bay Area (GBA) remained stable in the first quarter of 2026 despite ongoing geopolitical and trade headwinds, notably oil price shocks and continued repercussions from the Middle East conflict.Maintaining Momentum Amid HeadwindsThe Q1 findings largely captured activity and business sentiment since the Middle East conflict began in late February, which has remained highly uncertain and weighed on overall business and market sentiment.Despite a reduced appetite for expansion amid persistent geopolitical uncertainties, business sentiment remained steady across the GBA. The “current performance” index for business activity in Q1 edged down marginally to 49.9 from 50.3 in the previous quarter, while the “expectation” index moderated to 50.4 from 51. Both indices hovered around the 50-neutral mark, indicating GBA corporates’ resilience, supported by favourable policies announced by the Chinese Government aimed at boosting the domestic economy, which in turn would partially offset the fallout of the Middle East conflict.The “current performance” index came down mainly driven by “raw material inventory”, “fixed asset investment” and “financing scale”. The latter two readings were believed to reflect more cautious sentiment among businesses in light of the Middle East conflict. Meanwhile, “production/ sales”, “prices of finished goods/ services” and “profits” all experienced quarter-on-quarter expansion.The “expectations” index remained modestly positive, despite heightened external uncertainties. “New orders” held steady at 51.5, while “prices of finished good/ services” rose to 58.5. However, “profits” fell below the 50-watershed level, implying surveyed companies did not view price increases as sufficient to offset a likely rise in energy and material costs.Hong Kong to Sustain a Still-solid Growth PaceBy city, Hong Kong is expected to maintain a solid performance going forward. Although both the “current” and “expectation” sub-indices edged down to 52.7, these readings still comfortably stayed in expansionary territory, supported by improvements in “financial services” and “innovation and technology” sectors.Tommy Wu, Senior Economist, Greater China and North Asia, Standard Chartered, said: “In addition to the initial impact of surging global energy and freight costs, there are concerns about second-round impacts, such as higher input costs and weaker global demand. This is aligned with the latest reading, which shows a 2.3-point decline in “new export orders” to 47.5 for “current performance”, indicating a more cautious outlook for export demand. With the prolonged Middle East conflict, we anticipate global energy prices to be higher for longer and the second-round effects to become more visible in the coming months. These will likely weigh on business sentiment and appetite on making fixed investment. Nevertheless, Hong Kong has once again demonstrated its resilience amid market turbulence, and such resilience is expected to attract more global capital into HKD and Renminbi assets as safe-haven allocation.”Demand-boosting Measures Favour GBA BusinessesThe survey also investigated the impacts of a series of supportive policies from the Chinese government aimed at stimulating domestic demand in its thematic section. Among the new policy measures introduced by the Ministry of Finance in January, most respondents cited “loan interest subsidies for small, medium and micro-sized enterprises” (38.4%), “large-scale equipment upgrade subsidies” (36.9%) and “consumer goods trade-in subsidies” (31.7%) as the top domestic demand-boosting policies likely to have the most positive impact on their business.Wing Chu, Deputy Director of Research, HKTDC, said: “Demand-boosting stimulus is generating tangible benefits for GBA companies, helping to cushion external challenges amid the Middle East conflict. Targeted support, including loan interest subsidies, alongside measures aimed at stimulating consumer spending, is underpinning demand and supporting business activity across the GBA. Overall, policy-led demand support continues to serve as a meaningful tailwind for GBA businesses. While cost pressures and market competition remain key concerns, respondents are considering stepping up investment in talent and market promotion to sustain further business growth.”While many respondents believe stimulative policies could benefit their businesses by boosting online sales (36.6%) and reducing operating costs (33.8%), challenges faced by GBA corporates remain. Specifically, 54.9% of respondents identified labour costs as the biggest pressure point for their businesses, followed by rental costs (41.7%) and market competition (33.3%). Zooming into Hong Kong respondents, market competition was viewed as a more pressing challenge than rental costs, likely due to the increase in cross-border travel and change in consumption behaviours in recent years. In these circumstances, 38.7% would prioritise their investment in talent recruitment, followed by market promotion (38.1%) and personnel training (36.7%).About the GBAIThe GBAI is the first forward-looking quarterly survey in the market that looks at the business sentiment and synergistic effects in cities and industries across the GBA. It is compiled based on a survey of more than 1,000 companies in the GBA covering the manufacturing and trading, retail and wholesale, financial services, professional services and innovation and technology sectors. The index enables investors and businesses to better understand the current business climate, gauge future performance prospects and formulate their market strategies for the GBA.Related materialsStandard Chartered GBA Business Confidence Index Report: https://www.sc.com/hk/gba/gba-index-report/HKTDC Research: https://research.hktdc.com/en/article/MjMwNjM2MTgxMQReport and photos download: https://bit.ly/4u3izEMWing Chu, Deputy Director of Research, HKTDC (right), and Tommy Wu, Senior Economist, Greater China and North Asia, Standard Chartered (left), announced the latest GBA Business Confidence Index (GBAI) on 27 April 2026.Media enquiriesCorporate Affairs DepartmentStandard Chartered Bank (Hong Kong) Limited Flora Chiu Tel: (852) 3843 2285 Email: flora.chiu@sc.com Communications & Public Affairs DepartmentHKTDC Christy LeeClayton Lauw Tel: (852) 2584 4369Tel: (852) 2584 4472Email: christy.wn.lee@hktdc.orgEmail: clayton.y.lauw@hktdc.orgAbout Standard CharteredWe are a leading international banking group, with a presence in 54 of the world’s most dynamic markets. Our purpose is to drive commerce and prosperity through our unique diversity, and our heritage and values are expressed in our brand promise, here for good.Standard Chartered PLC is listed on the London and Hong Kong stock exchanges.The history of Standard Chartered in Hong Kong dates back to 1859. It is currently one of the Hong Kong SAR’s three note-issuing banks. Standard Chartered incorporated its Hong Kong business on 1 July 2004, and now operates as a licensed bank in Hong Kong under the name of Standard Chartered Bank (Hong Kong) Limited, a wholly owned subsidiary of Standard Chartered PLC.For more stories and expert opinions please visit Insights at sc.com. Follow Standard Chartered on X, LinkedIn, Instagram and Facebook.About HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedIn Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月27日 - (亞太商訊 via SeaPRwire.com) - 香港貿易發展局（香港貿發局）七大時尚生活產品及授權盛事今日揭幕，包括於今天至4月30日在灣仔香港會議展覽中心舉行的香港禮品及贈品展（禮品展）、香港時尚家品及家紡展（Home InStyle）、香港時裝節（Fashion InStyle），以及於亞洲國際博覽館舉行的香港國際印刷及包裝展（印包展）和香港奢侈品包裝展。而香港國際授權展（授權展）及亞洲授權業會議則由今天至4月29日在灣仔會展舉行。六項展覽共吸引來自超過30個國家及地區、約5,600家展商參與。香港貿發局總裁張淑芬表示：「香港一直是環球企業通往中國內地的主要門戶，擔當連接中國內地龐大市場與世界各地間的『超級聯繫人』和『超級增值人』的角色。香港憑藉穩固的優勢、完善的創新生態系統及知識產權基建，是企業拓展業務、實現創新發展，及將成果商業化的理想地。」創意禮品及家品薈萃 禮品展及Home InStyle成新品發佈平台禮品展與Home InStyle為買家帶來多元化禮品及家品選擇，產品涵蓋文化及創意、可持續發展、創新物料、樂齡科技等範疇。部份焦點內容集中於會展五樓展覽廳的全新Reimagine主題樓層，讓買家一站式掌握環球最新時尚家品及禮品方案，啟發業界想像未來產品的更多可能，帶來新視角及靈感。兩展亦吸引展商作發佈新產品平台。禮品展展商唯一冷熱水壺廠（展位：1E-D02）首次推出由香港插畫師 Pen So 與香港當代藝術家曹志豪設計的MINI20保溫杯盲盒。適逢其駱駝牌品牌與李小龍誕辰同樣迎來85周年，該展商亦推出另一聯乘保溫壺款式。Home InStyle展商百隆人工智能 （展位：5E-C20）首次展出防感染流動廁所，免安裝、無需用水，使用前後均無需重複消毒和接觸排泄物，更提供健康監測方案，將專業護理無縫融入現代家居。禮品展主打設計精品及訂製禮品禮品展於會展一樓展覽廳的卓越廊雲集超過100家本地及環球展商，主打高端及具設計特色的產品，涵蓋文具、家居用品及配備嶄新科技的智能精品。星光實業（展位：1C-G03）帶來紅 A「香港製造」迷你系列盲盒，以經典家品喚起1960至1990年代香港生活記憶。滙賢集團有限公司（展位：1C-E05）則展示為匹克球愛好者而設的 Napier Coded 背包，採用回收物料製成，結合運動與環保元素。Home InStyle引領家居新趨勢由創新科技署資助的樂齡科技及創新物料館（展位：5E-C20）設於Home InStyle，匯聚超過20家本地企業，展示樂齡科技產品、智能生活方案及創新物料家品。Scan Infinity Ltd帶來 TechFitX 智能運動訓練系統，透過切換組件及遊戲形式訓練， 讓長者輕鬆在家建立運動習慣。聯合國嶺南大學人道創新及科技中心展出 IntuCREW 智慧動力輔助解決方案，減輕照顧者推輪椅的體力負擔。其他產品包括聖諾盟 (Sinomax) 的仿生音波哄睡寶、德國寶 (German Pool) 的自然養生機，以及雅芳婷 (Afontane) 的自動清潔床上用品。創新物料方面，德塘瑞華國際股份有限公司展示以蓮花莖製成的可生物分解餐具及餐盒，以及蓮花纖維除臭貓砂； Editecture展出以回收塑膠瓶及瓶蓋碎片製成的 reEDIT 升級再造椅；Mush Composites則展示以農業副產品及菌絲體製成的生物基瓷磚，可應用於裝飾表面。Home InStyle另一焦點文創體驗區集合來自超過10個國家及地區、逾110家設計機構及文化品牌參與。當中包括印尼展商 PT MANAMU ANAIA SUMBA（展位：5E-C09A）帶來巴諾拉手鐲、捷克展商Izaak Reich Crystal s.r.o. (展位：5E-A14)展示超過150年歷史的手工玻璃、英國展商Block Design(展位：5E-C09B)的雙面造型玻璃花瓶、台灣展商Karari（展位：5E-A18）的線香器物、以及澳門展商（展位：5E-A16）的3D打印產品等。大會再度聯乘Pantone，以 2026 年度代表色「雲上舞白」為主題，打造不同家居陳列場景，幫助買家了解如何運用色彩配搭塑造時尚家居。Fashion InStyle展示環球時尚物料創新應用由香港貿發局主辦、香港特別行政區政府「文創產業發展處」資助的焦點展區NEXT@Fashion InStyle (NEXT)今年再度登場，展示時裝界如何通過創新物料引領產業變革、實踐永續發展。今年特別邀請菲律賓作為合作夥伴，並得到菲律賓駐香港貿易投資中心（PTIC-HK）及國際貿易展覽和代表團中心（CITEM）全力支持。而NEXT展區匯聚超過60家環球展商，覆蓋地域廣闊，當中有來自比利時的 Bloom Biotech （展位：3F-F09），展出微藻皮革，是首款採用可擴展綠色科技製的碳中和皮革替代品；而來自芬蘭的 Spinnova PLC（展位：3F-E04）展示以木材或廢棄纖維素製成的 SPINNOVA(R)新一代紡織纖維，適用於傳統紡織工藝，並可與棉纖維無縫混紡，為服裝及其他領域提供可擴展、可循環利用的紡織解決方案；而來自越南的 Thai Son S.P Co., Ltd.（展位：3F-F03）帶來多款織物，包括已有3000多年歷史的苧麻纖維不僅具有優異性能，更具有天然抗菌特性。NEXT展區還有來自香港、中國内地、泰國、印尼、冰島、瑞典、美國等地的展商展出各種創新物料。今年NEXT繼續邀請當代時尚品牌 Self-Portrait 創辦人兼創意總監 Han Chong 擔任項目顧問，帶領六組本地設計師及品牌組合，從八家物料供應商精選前瞻物料，傾力打造跨界企劃。今年更會首次利用香港及中國内地以外的物料進行設計，為時尚物料帶來新衝擊。如設計品牌WILSONKAKI將由法國供應商Chargeurs PCC提供的全球最輕H2物料、印尼供應商MYCL提供的菌絲皮革和香港供應商Texwinca提供的天然纖維糅合，透過層壓及黏合工藝，製作出兼具輕盈防護與自然觸感的日常單品。各組設計成品將在明天（4月28日）的時裝巡禮亮相。Fashion InStyle亦設有更多展區，包括設計師舞台、輔料及布料、時尚配飾、女裝、新娘禮服及晚裝、運動時尚等，展示各款成衣及配飾設計。Glory G International Limited（展位：3G-B31）展出「柔韌」系列輕質猄皮丹寧，打破牛仔褸沉重刻板印象；香港海源有限公司（展位：3G-F18）展出兼具裝飾性與實用性，可掛在手袋、鑰匙等物件作日常配搭的流蘇掛飾；來自烏茲別克的 Bibi Hanum（展位：3F-G29）則帶來具傳統特色的絲綢伊卡拼接裹身裙。印包展及奢侈品包裝展呈現綠色方案與高端工藝由貿發局和華港國際展覽有限公司主辦的印包展及香港奢侈品包裝展，展示創新、環保及高端印刷包裝方案。印包展展商環亞印刷包裝有限公司（展位：3-E01）推出的FSC無塑料纖維素膜包裝及FSC半透明紙袋，主打無塑膠及可回收，充分體現環保理念。寶紳國際香港有限公司（展位：3-E02）則帶來RFID（無線射頻識別）標籤，其內層以紙為原材料，兼顧永續設計。廣州市星啟元貿易有限公司 (展位：3-E11) 展示以農業廢料為原料的環保濕壓紙塑包裝，兼具實用性與環保價值。至於奢侈品包裝展，雅雋商務拓展（展位：3-A05）帶來立體旋轉音樂盒及復古留聲機禮盒，結合音樂播放、收納功能及高端包裝。美新隆（集團）有限公司（展位：3-A08）的紙燈籠花鳥罐採用一罐兩用設計，延長產品使用週期；亦帶來維港日夜光影禮盒，結合光影效果和收納功能，用於精緻食品包裝。授權展首設知識產權及電子商貿支援服務專區 拓展線上商機香港國際授權展匯聚來自香港、中國內地及亞洲各地超過 330 家參展商，展示超過 600 個品牌及知識產權項目，涵蓋藝術及文化、動畫與角色、品牌延伸、娛樂及體育授權等多個領域。展會首設知識產權及電子商貿支援服務專區，以配合特區政府積極提升港商在跨境電商平台競爭力的政策方向。專區匯聚多家電商平台、KOL、營銷及公關公司，包括電商平台Digitify Online Growth (展位：5G-E04）及營銷公司Matrix Promotion Limited (展位：5G-F01），支援品牌及知識產權項目把握電商發展帶來的新機遇。各大電商商會在展會期間舉辦包括搭建電商平台、透過電商平台「出海」和直播帶貨等相關的工作坊，協助業界掌握先機。授權展焦點 IP 包括 9GAG Limited 的 Potatoz（展位：5G-D20）、Toyzeroplus Limited 的 罐頭豬LULU（展位：5G-A24）、Yogurt Studio Ltd. 的 Café de Bollo（展位：5F-G20），以及來自中國內地的 乖巧寶寶（展位：5G-A22）、韓國的 LOTTY FRIENDS （展位：5F-G36）和泰國的 Warbie Yama（展位：5G-A51）等。由創意創業會主辦，香港特區政府文創產業發展處贊助的「香港設計授權‧支援計劃」在香港國際授權展續設「DLAB香港館」，雲集近40家展商，展示多個香港原創品牌及IP。大會亦再次與香港恒生大學、香港浸會大學及香港理工大學合作，並加入香港知專設計學院，舉辦香港授權新力量展區，展示本港新晉創意人才的創意設計。與展會同期舉行的亞洲授權業會議，邀請業界領袖探討多項市場焦點議題，當中今天會議邀請國際授權業協會行政總裁Maura Regan分享「2026年全球授權業趨勢展望」。適逢世界盃於今年舉行，會議亦邀請到國際足球協會(FIFA)高級授權經理Alessandro Villa及香港山成集團創辦人兼行政總監陳華俊分享成功體育授權後的商業策略。COVER株式會社執行副總裁兼銷售本部長毛延熙，將在明天探討虛擬 YouTubers (VTubers) 如何透過具策略性的社交媒體互動，與 Z 世代建立連結。研討會論壇探索市場新機遇為協助業界掌握最新發展趨勢，展會期間將舉辦約60場主題研討會、買家論壇、產品推廣及發佈會。內容聚焦銀髮經濟、市場趨勢、文化與創新，以及永續發展等熱門主題。其中，印包展及奢侈品包裝展其中一場研討會由貿發局與香港數碼印刷協會合辦，以「從指令到現實：生成式AI與數碼印刷的創意視覺革命」為題，分享生成式人工智能與數碼印刷如何推動創新轉型。禮品展與Home InStyle將舉行「循環再禮：永續家居與禮品設計的趨勢與突破」研討會，探討可持續設計的新方向。Fashion InStyle則會舉辦「文化融合×生活設計：『流行紋化』的超現實美」研討會，為業界帶來最新市場分析、創新思維及實踐策略。圖片下載：https://bit.ly/4vQE39E香港貿發局舉辦的香港禮品及贈品展、香港時尚家品及家紡展（Home InStyle）、香港時裝節（Fashion InStyle）、香港國際印刷及包裝展、香港奢侈品包裝展，以及香港國際授權展及亞洲授權業會議今天在香港會議展覽中心揭幕，六個展覽項目匯聚來自超過30個國家及地區、約5,600家展商。香港貿發局總裁張淑芬今早（4月27日）出席香港國際授權展與亞洲授權業會議開幕典禮，並為活動致開幕辭。（左起）文創產業發展處文創產業專員黎細明、亞洲旅遊交流中心主任張棟、香港貿發局總裁張淑芬、香港特區政府文化體育及旅遊局常任秘書長沈鳳君、泰國文化部Plan and Policy Analyst Expert Level Narathorn Parndee及國際授權業協會行政總裁Maura Regan共同主持開幕儀式。禮品展內的卓越廊雲集高端且具設計特色的禮品，涵蓋文具、家居用品及配備嶄新科技的智能精品。Home InStyle的樂齡科技及創新物料館，匯聚超過20家本地企業，展示樂齡科技產品、智能生活方案及多款可應用於家品及家紡市場的創新物料。文創體驗區集中展示環球文創家品，匯聚具有文化創意及獨特風格的設計師品牌。Fashion InStyle今年設有焦點展區NEXT@Fashion InStyle，項目合作夥伴菲律賓帶來超過25家展商展出當地時尚物料。NEXT@Fashion InStyle項目顧問Han Chong（中）帶領六組本地設計師及品牌打造多款選用精選環球創新物料的時裝設計。於印包展亮相的寶紳國際香港有限公司展示RFID（無線射頻識別）標籤，內層以紙為原材料，兼顧功能與永續設計。美新隆(集團)有限公司於奢侈品包裝展帶來維港日夜光影禮盒，結合光影效果和收納功能，用於精緻食品包裝。香港國際授權展今年首設知識產權及電子商貿支援服務專區。香港貿發局新聞中心：http://mediaroom.hktdc.com/tc香港禮品及贈品展：http://www.hktdc.com/event/hkgiftspremiumfair/tc香港時尚家品展 (Home InStyle)：https://www.hktdc.com/event/homeinstyle/tc香港國際家用紡織品展 ：www.hktdc.com/event/hkhometextilesfair/tc香港時裝節 (Fashion InStyle)：www.hktdc.com/event/fashioninstyle/tc香港國際印刷及包裝展：https://www.hktdc.com/event/hkprintpackfair/tc香港國際授權展：https://www.hktdc.com/event/hklicensingshow/tc亞洲授權業會議：https://www.hktdc.com/event/hklicensingshow/tc/programme?category=all&date=all傳媒查詢新聞界如有查詢，請聯絡：香港時尚家品及家紡展(Home InStyle)、香港時裝節(Fashion InStyle)、香港禮品及贈品展、香港國際印刷及包裝展及香港奢侈品包裝展：Pandagon公關公司： 李彥煒電話：6083 5623電郵：pandagon.limited@gmail.com 香港貿發局傳訊及公共事務部： 劉茸電話：2584 4472電郵：clayton.y.lauw@hktdc.org香港國際授權展及亞洲授權業會議：言十公關公司： 劉碧思電話：6187 7786電郵：molisalau@raconteur.hk謝媛彰 電話：9742 7338電郵：betsytse@raconteur.hk 香港貿發局傳訊及公共事務部： 簡惠宜電話：2584 4055電郵：winnie.wy.kan@hktdc.org香港貿易發展局簡介香港貿易發展局(香港貿發局)今年慶祝成立60周年！成立於1966年，香港貿發局是負責促進、協助和發展香港貿易的法定機構。香港貿發局在世界各地設有超過50個辦事處，其中13個設於中國內地，致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團，為企業(尤其是中小企)開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台，提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊，請瀏覽www.hktdc.com/aboutus/tc。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年4月27日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（867.HK/8A8.SG）（"康哲藥業"）欣然宣佈，近期，康哲藥業通過其全資附屬公司與Pharmacosmos A/S就異麥芽糖酐鐵注射液（"莫諾菲(R)"）和右旋糖酐鐵注射液（"科莫非(R)"）簽訂獨家商業化與供應協議（"協議"）。根據協議，康哲藥業獲得了在中華人民共和國（就本協議而言，不含香港特別行政區、澳門特別行政區、臺灣地區）獨家商業化產品的權利，Pharmacosmos A/S繼續負責生產、供應產品。合作期限為協議約定的生效之日起十五年，到期前雙方可友好協商延長。本次合作的兩款靜脈鐵劑均為原研藥，已在中國獲批上市並納入國家醫保目錄。其中，莫諾菲(R)為獨家藥，是中國首款獲批上市的第三代靜脈鐵劑，具有更穩定的創新矩陣式納米結構，安全性更優[1]，可一次足量補鐵，顯著減少輸注次數、更快提升血紅蛋白水平，提高臨床便捷性。另一款產品科莫非(R)為目前中國唯一被納入國家醫保目錄甲類，也是唯一被納入國家基本藥物目錄的靜脈鐵劑，臨床應用多年，其有效性與安全性已得到累積的臨床經驗和已發表數據的支持。上述兩款產品將形成覆蓋全渠道、全場景的靜脈補鐵產品矩陣，可滿足不同層級醫療機構、不同類型缺鐵性貧血患者的臨床需求，為患者提供更多元化、安全、高效的治療選擇。鐵缺乏症/缺鐵性貧血患者廣泛分佈於消化、心內、腎內、婦產、骨科等多個科室，均為康哲藥業的優勢專科領域，兩款產品的加入將與其現有在售產品的專家資源、學術推廣網絡高效協同，進一步強化康哲藥業在貧血治療領域的整體競爭力，並預期對其業績產生積極正面影響。關於莫諾菲(R)的更多信息莫諾菲(R)已於2021年1月30日獲批，用於治療口服鐵劑無效、無法口服補鐵或臨床需快速補鐵時的缺鐵狀況。2023年被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》（醫保目錄）乙類醫保。莫諾菲(R)由納米顆粒組成，其結構穩定、呈基質樣，由鐵原子層與短鏈線性异麥芽糖碳水化合物層交替構成。該結構可實現可控的鐵釋放，游離鐵含量更低，從而有助於形成良好的安全性特徵，包括較低的超敏反應和低磷血症風險。莫諾菲(R)可實現單次高劑量靜脈輸注給藥1000mg或更高劑量，而較早的療法（如蔗糖鐵）通常需要多次給藥，每次僅100至200 mg。因此莫諾菲(R)一次治療即可實現足量補鐵，减少輸注次數，減輕醫患負擔，並提升輸注能力。同時，其低磷血症風險較低，有助於避免骨折等併發症，並支持改善疲勞症狀（缺鐵性貧血關鍵症狀之一）。關於科莫非(R)的更多信息科莫非(R)為第二代低分子量右旋糖酐鐵注射液，於2003年在中國大陸獲批上市，用於無法口服鐵劑的缺鐵病人（如不耐受或口服鐵劑治療不滿意），同樣可實現單次大劑量足量補鐵。科莫非(R)憑藉多年臨床應用積累，其有效性與安全性已得到累積的臨床經驗和已發表數據的支持，其甲類醫保與基藥的雙重資質，支持其基層臨床補鐵的核心地位。關於鐵缺乏症和缺鐵性貧血鐵缺乏症（iron deficiency，ID）和缺鐵性貧血（iron deficiency anemia，IDA）是普遍影響兒童、停經前女性（尤其是孕婦）及老年人的全球性健康問題，可對多系統器官功能造成損害，引發生長發育遲緩、行為障礙、認知功能損傷、體能受損、圍產期及圍手術期併發症等一系列健康問題，亦會嚴重影響消化系統疾病、慢性腎臟疾病、心力衰竭及腫瘤等慢性疾病的預後[2]。超過10億人患有缺鐵性貧血[3]，使其成為全球疾病負擔的主要因素之一[4]。中國第4次營養調查數據顯示，居民IDA患病率為20.1%[5]，但醫患雙方重視程度不足，輕度貧血獲診治者不足20%，極重度貧血者亦僅50%獲診治，ID/IDA存在明顯診斷不及時及治療率偏低的情況[2]。補鐵為ID/IDA的常規治療方式，分為口服補鐵與靜脈補鐵，其中靜脈鐵劑是口服鐵劑不耐受、口服鐵劑療效不佳、臨床需快速補鐵、患者希望1-2次補足鐵量等情境下的重要手段[1,2,6]。但因對IDA重視不足、服藥依從性、住院時間、輸液便利性等條件限制，加上對靜脈鐵劑安全性的顧慮導致靜脈鐵劑使用較為保守。中國真實世界研究顯示，IDA患者蔗糖鐵使用總劑量均值為511mg，遠未達目標劑量1000mg[2]。臨床亟需安全性高、補鐵療效佳、可一次足量補鐵的靜脈鐵劑產品。莫諾菲(R)與科莫非(R)構建覆蓋全場景的靜脈補鐵產品矩陣，為缺鐵性貧血患者提供分層診療選擇。關於Pharmacosmos A/SPharmacosmos A/S為碳水化合物化學及缺鐵與缺鐵性貧血創新治療領域的全球領先企業。公司憑藉在碳水化合物化學與細胞週期生物學的深厚專業積累，致力於針對未被滿足的患者需求開發創新療法，重點關注鐵代謝及血液相關疾病。公司成立於1965年，總部位於丹麥，團隊由來自英國、愛爾蘭、北歐、德國、美國、加拿大及中國的700多名專家組成。憑藉優異的產品質量與臨床價值，核心鐵劑產品已於全球多個國家及地區獲批上市並廣泛應用，積累深厚技術實力與優質市場口碑。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腎代謝/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。參考文獻/資料1. 中國藥理學會藥源性疾病學專業委員會. 廣東省藥學會. 靜脈鐵劑的臨床應用和藥學監護專家共識（2024）[J]. 藥物不良反應雜誌, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃000702. 廖敏婧, 張連生. 鐵缺乏及缺鐵性貧血規範化診治[J]. 中華內科雜誌, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.3. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.4. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.5. 李莉娟, 張連生. 缺鐵性貧血規範化診治的若干問題[J]. 中華醫學雜誌, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.6. 中華醫學會血液學分會紅細胞疾病（貧血）學組. 鐵缺乏症和缺鐵性貧血診治和預防的多學科專家共識（2022年版）[J]. 中華醫學雜誌, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想了解具體疾病診療信息，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Apr 27, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement (the “Agreement”) with Pharmacosmos A/S for Iron Isomaltoside Injection (“Monofer®”) and Iron Dextran Injection (“Cosmofer®”) recently. In accordance with the Agreement, the Group has obtained an exclusive right to commercialize the products in the People’s Republic of China (for the purpose of this Agreement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan region). Pharmacosmos A/S will continue to manufacture and supply the products. The cooperation term shall be fifteen years from the effective date stipulated in the Agreement, which may be extended upon mutual agreement between the parties prior to expiry.The two intravenous iron therapies under this cooperation are both originator products that have been approved for marketing in China and included in the China’s National Reimbursement Drug List (NRDL). Among them, Monofer® is an exclusive drug and the first third-generation intravenous iron therapy approved for marketing in China. It features an innovative and more stable matrix-like nanostructure and provides a superior safety profile[1]. Its single-dose full iron replenishment significantly reduces the number of infusions, enables faster improvement in hemoglobin levels and enhances clinical convenience. Another product, Cosmofer®, is currently the only intravenous iron therapy included in Category A of the NRDL and also the only one included in the National Essential Medicines List (NEML). With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data.The above two products will form a comprehensive intravenous iron product portfolio covering all channels and treatment scenarios, which can support meeting the clinical needs of different levels of healthcare institutions and different types of iron deficiency anemia (IDA) patients, providing more diversified, safe and effective treatment options for patients. Patients with iron deficiency (ID) and IDA are widely distributed across multiple clinical departments, including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics, which are all key specialty areas of the Group. The addition of the two products will generate efficient synergies with the Group’s existing marketed products in expert resources and academic promotion network, further strengthening the Group’s overall competitiveness in the field of anemia treatment, and is expected to have a positive impact on the Group’s performance.More information about Monofer®Monofer® was approved on 30 January 2021 for the treatment of iron deficiency in patients where oral iron preparations are ineffective, cannot be used, or where there is a clinical need for rapid iron supplementation. In 2023, Monofer® was included in the NRDL as a Category B reimbursable drug. Monofer® consists of nanoparticles with a stable, matrix-like structure composed of interchanging layers of iron atoms and short, linear isomaltose carbohydrates. This structure enables controlled iron release with low levels of labile iron, contributing to a favourable safety profile, including a low risk of hypersensitivity reactions and hypophosphatemia. Monofer® can be administered as a high-dose infusion of 1,000 mg or more in a single visit, whereas older therapies such as iron sucrose typically require repeated administrations of 100 to 200 mg. This enables full iron repletion in one treatment, reducing the need for multiple infusions, lowering the burden on patients and healthcare systems, and increasing infusion capacity. At the same time, the low risk of hypophosphatemia helps avoid complications such as fractures and supports recovery from fatigue, a key symptom of iron deficiency anaemia.More information about Cosmofer®Cosmofer® is a second-generation low-molecular-weight iron dextran injection. It was approved for marketing in Mainland China in 2003 and is indicated for patients with iron deficiency who cannot take oral iron preparations (such as those who are intolerant to oral iron or have unsatisfactory therapeutic outcomes). Cosmofer® also allows single-dose high-dose iron repletion. With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data. Its dual status as a Category A NRDL-listed product and NEML supports its core role in iron supplementation in primary healthcare settings.About Iron Deficiency and Iron Deficiency AnemiaID and IDA are global health issues that commonly affect children, premenopausal women (particularly pregnant women) and the elderly. These conditions may impair the function of multiple organ systems, leading to a series of health problems such as growth retardation, behavioral disorders, cognitive impairment, reduced physical capacity, and peri-natal and peri-operative complications. They also significantly affect the prognosis of chronic diseases such as gastrointestinal diseases, chronic kidney disease, heart failure and tumors[2]. More than 1 billion people live with iron deficiency anaemia[3], making it one of the leading contributors to the global burden of disease[4]. Data from the Fourth National Nutrition Survey in China indicate that the prevalence of IDA among Chinese residents is 20.1%[5]. However, both patients and healthcare professionals have insufficient awareness of the disease. Less than 20% of patients with mild anemia receive diagnosis and treatment, while only about 50% of patients with severe anemia receive appropriate diagnosis and treatment[2]. This indicates significant underdiagnosis and undertreatment of ID/IDA. Iron supplementation is the standard treatment for ID/IDA and includes oral iron therapy and intravenous iron therapy. Intravenous iron therapy is an important option for patients who cannot tolerate oral iron, have inadequate response to oral therapy, require rapid iron repletion, or prefer full iron supplementation within one to two administrations[1,2,6]. However, due to insufficient awareness of IDA, patient adherence issues, hospitalization constraints, infusion convenience, and safety concerns regarding intravenous iron therapies, the clinical use of intravenous iron in China remains relatively conservative. A Chinese real-world study shows that the average total dose of iron sucrose used in IDA patients was approximately 511 mg, which was significantly lower than the target dose of 1,000 mg[2]. There is therefore a significant clinical need for intravenous iron therapies that offer high safety, strong demonstrated efficacy and single-dose full iron repletion. Monofer® and Cosmofer® together establish a comprehensive intravenous iron product portfolio covering multiple treatment scenarios, providing tiered treatment options for patients with iron deficiency anemia.About Pharmacosmos A/SPharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anemia. Leveraging its deep expertise in carbohydrate chemistry and cell cycle biology, the company is committed to developing innovative therapies to address unmet patient needs, with a particular focus on iron metabolism and hematology-related diseases. Pharmacosmos A/S was founded in 1965 and is headquartered in Denmark, and employs more than 700 specialists from the United Kingdom, Ireland, the Nordic countries, Germany, the United States, Canada and China. With excellent product quality and strong clinical value, its core iron therapy products have been approved and widely used in multiple countries and regions worldwide, establishing strong technological capabilities and a solid market reputation.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. Chinese Pharmacological Society Professional Committee of Drug‑induced Diseases, Guangdong Pharmaceutical Association. Expert consensus of clinical application and pharmaceutical care for intravenous iron agents (2024) [J]. Adverse Drug Reactions Journal, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃000702. Liao Minjing, Zhang Liansheng. Standardized diagnosis and treatment of iron deficiency and iron‑deficiency anemia [J]. Chinese Journal of Internal Medicine, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.3. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.4. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.5. Li Lijuan, Zhang Liansheng. Considerations on the standardized diagnosis and treatment of iron‑deficiency anemia [J]. National Medical Journal of China, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.6. Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Multidisciplinary expert consensus on the diagnosis, treatment and prevention of iron deficiency and iron deficiency anemia (2022 edition) [J]. National Medical Journal of China, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - April 27, 2026) - Copper-gold explorer and hybrid project generator Kincora Copper Limited (ASX: KCC) (TSXV: KCC) (Kincora or the Company) is pleased to announce that it will be holding an Investor Webinar Presentation and Discussion on the afternoon of Tuesday April 28th Pacific Standard Time (PST) and morning of Wednesday 29th Australian Eastern Standard Time (AEST).President & Chief Executive Officer, Mr Sam Spring, will update the market on recent and upcoming drill programs, exploration activities and corporate developments across the project portfolio.Both Kincora shareholders and interested investors are invited to attend the webinar and participate in the accompanying Q&A session.Kincora Copper Investor Webinar Details: Canada(Vancouver)US(Dallas)Australia(East Coast)Date28-Apr-202628-Apr-202629-Apr-2026Time4.00PM PST6.00PM CT9.00AM AEST Please note: Registration is required to attend this Zoom format investor webinar.Please register in advance for the Zoom webinar using the following link:https://us02web.zoom.us/webinar/register/WN_IE079ntuTbmoCUiWm6_O5QAfter registering, you will receive a confirmation email containing information about joining the webinar.Questions can be submitted in advance of the webinar to Julia Maguire of The Capital Network via the following email address: julia@thecapitalnetwork.com.auA replay of the webinar will be available on Kincora's website on the following page:https://kincoracopper.com/interviews/About Kincora: Kincora Copper Limited (ASX: KCC) (TSXV: KCC) is an emerging Australia-focused gold-copper explorer with a hybrid project generator strategy.The Company is successfully proving up the prospectivity of its extensive project portfolio, which includes multiple district-scale landholdings and scalable drill ready targets. These assets are located in Australia's Lachlan Fold Belt and Mongolia's Southern Gobi, two of the globe's leading porphyry belts, and the historical Condobolin mining field within the Cobar basin in NSW.The Company has already unlocked over $100 million of potential partner funding for multiple earlier stage and/or non-core porphyry projects. These initial deals have supported over 18,000 metres of drilling and over A$9m of partner funded exploration since late 2024, with management fees and exploration ramping up.Partner discussions are ongoing for its remaining 100% owned flagship projects that are all situated within existing porphyry camps containing over 20-million-ounce gold equivalent resource inventory.By having a significant portfolio of partner funded large porphyry projects, and a very focused capital efficient programs at the Condobolin and other sole funded projects, the Company is seeking to position Kincora as a leading institutional grade explorer in the public Australian and Canadian markets, and the leading project generator on the ASX.The Company's website is: www.kincoracopper.comThis announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)For further information please contact:Sam Spring, President and Chief Executive Officersam.spring@kincoracopper.com or +61431 329 345 Laurie Thomas, Strategic Advisor laurie.thomas@kincoracopper.com or +1306 341 3826 Media contactJulia Maguire, Managing Director, The Capital Networkjulia@thecapitalnetwork.com.au or +61 2 7257 7338Executive office Subsidiary office Australia 400 - 837 West Hastings Street C/- JM Corporate ServicesVancouver, BC V6C 3N6, Canada Level 6, 350 Collins StreetTel: 1.604.283.1722 Melbourne, VIC, Australia 3000 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294246 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com